1 / 24

Lupus and Pregnancy: Challenges, Risks, and Outcomes

Learn about the complexities of managing systemic lupus erythematosus during pregnancy. Explore risks, outcomes, and management strategies for pregnant lupus patients presented by experts in rheumatology and obstetrics.

lhung
Télécharger la présentation

Lupus and Pregnancy: Challenges, Risks, and Outcomes

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Lupus and Pregnancy Prof. Munther A Khamashta MD FRCP PhDDirector: Graham Hughes Lupus Research Laboratory The Rayne Institute, St Thomas Hospital ( Dubai Hospital Rheumatology Department ) Challenges in Obstetrics & Gynaecology, Kuwait, February 2017

  2. Disclosures

  3. Lupus in pregnancy clinic – St Thomas’ Hospital

  4. Connective Tissue Disorders and Pregnancy St Thomas’ Hospital 1987-2015 • Systemic Lupus Erythematosus >1000 • Antiphospholipid syndrome >1000 • Sjögren’s Syndrome 90 • Rheumatoid arthritis 50 • Vasculitis 30 • Mixed Connective Tissue disease 20 • Systemic sclerosis/scleroderma 15

  5. SLE: heterogeneous multi-system progressive autoimmune disease.Many patients fluctuate/cycle. No established treatment algorithm Flares Time Remission Long Quiescent 10-15% Barr et al. ARTHRITIS & RHEUMATISM. Vol. 42, No. 12, December 1999, pp 2682–2688. Petri et al. Lupus (1999) 8, 685-691 Petri. RHEUMATIC DISEASE CLINICS OF NORTH AMERICA. VOLUME 26 - NUMBER 2 MAY 2000 Relapse Remitting 50-60% Chronic Active 20-25%

  6. What makes a pregnancy “high risk”? • Renal involvement • Antiphospholipid syndrome • Previous poor obstetric history • Cardiac involvement • Pulmonary hypertension • Restrictive lung disease (FVC < 1 litre) • Active disease. • Extractable nuclear antigens (Ro, La) Ateka-Barrutia O, Khamashta MA. Lupus. 2013;22:1295-308

  7. Pregnancy and Lupus Potential problems • Lupus flare: 40-50% • Miscarriages or stillbirths: 20-25% • Premature birth of the infant: 25% • Pre-eclampsia: 15-20% • Neonatal lupus: 1-3% (Ro-positive) Ruiz-Irastorza G, Khamashta MA. European journal of clinical investigation. 2011;41:672-8

  8. Renal involvement / hypertension • Increased risk of PET / IUGR / preterm delivery • Even quiescent lupus nephritis increases risk of fetal loss, especially if hypertensive or proteinuric • Risk of deterioration is higher with higher serum creatinine • Chance of successful outcome is lower with higher serum creatinine • Delay pregnancy for 6 months after renal flare

  9. SLE with and without Lupus Nephritis SLE + Nephritis (43) SLE – Nephritis (64) Maternal Outcome Pre-eclampsia 12 (28.6%) 10 (16.9%) Thrombus 0 1 (1.7%) Flare 14 (41.2%) 22 (37.3%) Neonatal Outcome IUD 1 (2.9%) 1 (1.7%) NND 1 (2.9%) 0 Gestation 36.7± 4.2 38.2 ± 3.0 % <34/40 8 (19%) 2 (3%) % <37/40 13 (30%) 7 (11%) 2963 ± 717 Birth Weight (g) 2715 ± 862 %<10th Centile SGA 14 (33%) 14 (23.3%) Bramham K et al. J Rheumatol 2011;38:1906-13

  10. Increasing proteinuria • Physiological • Pre-eclampsia • Nephritic flare

  11. Nephritic flare / Pre-eclampsia

  12. Mid-trimester uterine artery Doppler screening as a predictor of pre-eclampsia • In high-risk women better than clinical risk assessment • Positive predictive values up to 60% • Negative predictive values up to 92% Coleman, McCowan & North Ultrasound Obstet Gynecol 2000 Normal Early Diastolic Notching

  13. NEONATAL LUPUS Passively Acquired Autoimmunity MATERNAL CIRCULATION PLACENTAL TRANSPORT FETAL CIRCULATION anti-Ro/La Abs FcRn anti-Ro/La Abs CLINICAL FEATURES Congenital AV block/Cardiomyopathy CARDIAC CUTANEOUS • Risk 2% if no affected childIn utero 18-28 wks • Unique to the fetus • Permanent, high morbidity/mortality • Risk 5% • Birth →6 wks, UV-provoked • Resembles adult SCLE • Transient, rare scarring

  14. Neonatal lupus 3 weeks 3 months

  15. Congenital Heart Block • Appears in utero (18-28 weeks) • Fetal bradycardia • 50-60% of those who survive need pacemakers in early infancy (others in early teens) • Currently no treatment to prevent recurrence Recurrence rate 1 in 5 Brito-zeron p et al.Nat Rev Rheumatol 2015,11:301-12

  16. Experience of IVIG use (animal model) Fetal:maternal ratios of Ro and La antibodies were lower in IVIG group (p<0.001) Tran HB et al, Arthritis Rheum 2004

  17. Restriction of Analysis to 42 Pregnancies Following a Child with Cardiac NL in Two Recent Prospective Studies of IVIG, no Recurrences of Cardiac NL Occurred in Fetuses Exposed to Hyroxychloroquine 0/8=0% 7/34=20.6% Izmirly et al, Circulation 2012, 126:76-82.

More Related